NEWTOWN SQUARE, PA — ArriVent BioPharma Inc. (Nasdaq: AVBP) will present preclinical data on two cancer drug candidates at the American Association for Cancer Research Annual Meeting 2026 in San Diego from April 17 through April 22, the company announced.
The presentations will include data on firmonertinib, an EGFR inhibitor for non-small cell lung cancer, and ARR-002, an antibody drug conjugate targeting ovarian and endometrial cancers.
Firmonertinib data will be presented during a poster session on Tuesday, April 21, from 2:00 p.m. to 5:00 p.m. PT in the Experimental and Molecular Therapeutics session.
According to the company, preclinical findings demonstrate that firmonertinib inhibits both classical EGFR mutations and exon 20 insertion mutations, which are associated with limited treatment options.
The data include structural, biochemical and animal model evidence showing tumor inhibition and brain penetration, supporting the drug’s mechanism of binding to EGFR mutant proteins.
Firmonertinib is currently being studied in global Phase 3 trials for patients with EGFR exon 20 insertion mutations and PACC mutations, and has received Breakthrough Therapy and Orphan Drug designations from the U.S. Food and Drug Administration for certain lung cancer indications.
The company said the drug is also approved in China for specific EGFR-mutant non-small cell lung cancer indications.
ArriVent, in partnership with Aarvik Therapeutics Inc., will present data on ARR-002 during a poster session on Monday, April 20, from 9:00 a.m. to 12:00 p.m. PT in the Clinical Research session.
ARR-002, also known as AV-P138-ADC, is a dual-target antibody drug conjugate designed to bind MUC16 and NaPi2b proteins, which are expressed in ovarian and endometrial cancers.
According to the company, preclinical studies showed ARR-002 demonstrated improved tumor response in animal models compared to single-target therapies, along with evidence of simultaneous binding to both targets and enhanced internalization.
The company also reported a tolerability profile observed in non-human primates, with reversible hematologic effects at higher doses.
Data on ARR-002 will also be featured in an oral presentation by Aarvik during a clinical research mini symposium on Tuesday, April 21, from 2:30 p.m. to 4:30 p.m. PT.
ArriVent said the presentations build on earlier preclinical findings presented at prior AACR meetings and support continued development of both programs toward potential clinical applications.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.